Literature DB >> 182881

The role of circulating interferon in the modifications of immune responsiveness by mouse hepatitis virus (MHV-3).

J L Virelizier, A M Virelizier, A C Allison.   

Abstract

MHV-3 modifies the humoral immune response to SRBC. During acute infections timing was critical: infecting mice before antigen administration led to immunodepression. Simultaneous injection with virus and SRBC resulted in immunostimulation. Persistent MHV-3 infections were associated with a chronic immunodepression. The presence of circulating interferon (IF) was well correlated with these modifications. IF peaking before antigen was associated with immunodepression whereas IF secretion after antigen was associated with immunostimulation. Low, permanent levels of IF were associated with chronic immunodepression. Since IF is, up to now, the only product of activated lymphocytes that has been shown to modulate immune responses, our results suggest that induction of IF by MHV-3 may be the main mechanism by which this virus modifies immune responsiveness. Moreover, we have shown that MHV-3 infection in susceptible mice diminishes the secretion of lymphocyte IF in response to Sendai virus. In these animals, the thymus cortex was profoundly depleted although the thymus medulla remained unchanged. The MHV-3 infection may, therefore, interfere with a subpopulation of IF-secreting lymphocytes. The possible physiologic role of such lymphocyte subpopulation in terms of host-virus relationships is discussed.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 182881

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  19 in total

1.  Suppression of immune response induction in Peyer's patch lymphoid cells from mice infected with mouse hepatitis virus.

Authors:  D B Casebolt; D M Spalding; T R Schoeb; J R Lindsey
Journal:  Cell Immunol       Date:  1987-10-01       Impact factor: 4.868

2.  Production by mixed lymphocyte cultures of a type II interferon able to protect macrophages against virus infection.

Authors:  J L Virelizier; A C Allison; E de Maeyer
Journal:  Infect Immun       Date:  1977-08       Impact factor: 3.441

3.  Immunosuppressive effects of lymphocyte (type II) and leucocyte (type I) interferon on primary antibody responses in vivo and in vitro.

Authors:  J L Virelizier; E L Chan; A C Allison
Journal:  Clin Exp Immunol       Date:  1977-11       Impact factor: 4.330

4.  Immune reactivity of Visna virus-inoculated mice.

Authors:  B Svennerholm; O Strannegård; E Lycke
Journal:  Infect Immun       Date:  1978-05       Impact factor: 3.441

5.  In vivo and in vitro models of demyelinating disease: endogenous factors influencing demyelinating disease caused by mouse hepatitis virus in rats and mice.

Authors:  O Sorensen; R Dugre; D Percy; S Dales
Journal:  Infect Immun       Date:  1982-09       Impact factor: 3.441

6.  The use of cross-foster rederivation to eliminate murine norovirus, Helicobacter spp., and murine hepatitis virus from a mouse colony.

Authors:  James E Artwohl; Jeanette E Purcell; Jeffrey D Fortman
Journal:  J Am Assoc Lab Anim Sci       Date:  2008-11       Impact factor: 1.232

7.  Possible importance of macrophage-derived mediators in acute malaria.

Authors:  I A Clark; J L Virelizier; E A Carswell; P R Wood
Journal:  Infect Immun       Date:  1981-06       Impact factor: 3.441

8.  Cytokine induction during T-cell-mediated clearance of mouse hepatitis virus from neurons in vivo.

Authors:  B D Pearce; M V Hobbs; T S McGraw; M J Buchmeier
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

9.  Thymus involution induced by mouse hepatitis virus A59 in BALB/c mice.

Authors:  C Godfraind; K V Holmes; J P Coutelier
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

10.  Peritoneal macrophage alterations caused by naturally occurring mouse hepatitis virus.

Authors:  G A Boorman; M I Luster; J H Dean; M L Campbell; L A Lauer; F A Talley; R E Wilson; M J Collins
Journal:  Am J Pathol       Date:  1982-01       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.